Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
24 hedge funds and large institutions have $35.1M invested in Astria Therapeutics in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 6 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
6% more capital invested
Capital invested by funds: $33.1M → $35.1M (+$2.03M)
1.53% more ownership
Funds ownership: 36.35% → 37.88% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less funds holding
Funds holding: 28 → 24 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$850K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$533K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$491K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$432K |
| 5 |
JP Morgan Chase
New York
|
+$250K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$426K |
| 2 |
Millennium Management
New York
|
-$387K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$213K |
| 4 |
JT
Jump Trading
Chicago,
Illinois
|
-$187K |
| 5 |
OC
Oppenheimer & Co
New York
|
-$175K |
ATXS Hedge Fund Activity: Q2 2019 in Review
24 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q2 2019, worth a combined $35.1M — up 6.1% from $33.1M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ATXS and 2 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 9 added.
The largest buyer was BlackRock, adding an estimated $850K. The largest seller was Renaissance Technologies, cutting an estimated $426K.
- 24 institutional investors held Astria Therapeutics (ATXS) as of Q2 2019, down from 28 in Q1 2019.
- Funds reported $35.1M of Astria Therapeutics stock for Q2 2019, up 6.1% quarter-over-quarter.
- 2 funds opened new Astria Therapeutics positions in Q2 2019 and 6 closed out, a net change of -4 holders.
- The largest Astria Therapeutics buyer in Q2 2019 was BlackRock, an estimated $850K added.
- The largest Astria Therapeutics seller in Q2 2019 was Renaissance Technologies, an estimated $426K sold.
Based on aggregated 13F filings for Q2 2019.